Customised, individualised treatment of metastatic non-small-cell lung carcinoma (NSCLC)

Sultan Qaboos University Medical Journal

Volumn 13, Issue 2, 2013, Pages 202-217

  Furrukh, Muhammad ^a   Al Moundhri, Mansour ^b   Zahid, Khawaja F ^c   Kumar, Shiyam ^a   Burney, Ikram ^a  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^b SULTAN QABOOS UNIVERSITY   (Oman)

^c SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE   (Pakistan)

Author keywords

Bevacizumab; Biological markers; Carcinoma; Epidermal growth factor; Erlotinib; Lung neoplasm; Non small cell lung; Protein kinase inhibitors; Receptor; Vascular endothelial growth factor

Indexed keywords

EID: 84877797089     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: 10.12816/0003225     Document Type: Review

References (102)

1. Union for International Cancer Control. Agency for Research on Cancer. GloboCan 2008 Fast Stats. From: http://globocan.iarc.fr/factsheet.asp. Accessed: May 2012.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou Tatalovich Z, Cho H, et al. SEER Cancer Statistics Review 1975-2008 NCI Bethesda. From: http://seer.cancer.gov/csr?1975-2008/posted. Accessed: May 2012.
3. Ministry of Health. Cancer Incidence in Oman. From: www.moh.gov.om. Accessed: May 2012.
4. Yang R, Cheung MC, Pedroso FE, Byrne MM, Koniaris LG, Zimmers TA. Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival. J Surg Res 2011; 170:e75-83.
5. Burdett S, Johnson DH, Stewart L, Tierney J, Le Pechoux C for the NSCLC collaborative group. Supportive care and chemotherapy vs supportive care alone in advanced NSCLC: A meta analysis using individual patient data (IPD) from randomized controlled trials. J Thorac Oncol 2007; 2:S337.
6. Luu DCN, Mamet R, Zornosa CC, Niland JC, D'Amico TA, Kalemkerian GP, et al. Retrospective analyses of the impact of age on overall survival in patients with non-small cell lung cancer. J Clin Oncol 2012; e18018.
7. Tammemagi CM, Neslund-Dudas C, Simoff M. Impact of co-morbidity on lung cancer survival. Int J Cancer 2003;103:792-802.
8. Paik PK, Johnson ML, D'Angelo SP, Sima CS, Ang D, Dogan S, et al. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer 2012; 118:5840-7.
9. Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Cancer 1989; 63:1271-8.
10. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced NSCLC. N Engl J Med 2002; 346:92-8.
11. Ardizzoni M, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99:847-57.
12. NSCLC collaborative group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909.
13. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improved survival in advanced NSCLC: A systematic review and met analyses of individual patient data for 16 randomized controlled trials. J Clin Oncol 2008; 26:4617-25.
14. Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced stage NSCLC. J Clin Oncol 2008; 26:3543-51.
15. Ferrara N, Gerber HP, LeCouter I. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76.
16. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-9.
17. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-91.
18. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006; 355:2542-50.
19. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin & paclitaxel on ECOG 4599. J Clin Oncol 2010; 28:949-54.
20. Jyoti DP, Thomas AH, Alfred R, Eric MH, Mathew GB, Daniel TM, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsqamous NSCLC. J Clin Oncol 2009; 27:1-7.
21. Stevenson JP, Langer CJ, Somer RA, Evans TL, Rajagopalan K, Krieger K, et al. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, non-squamous non-small cell lung cancer. Cancer 2012;118:5580-7.
22. Barlesi F, de Castro J, Dvornichenko V, Kim JH, Pazzola A, Rittmeyer A, et al. AVAPERL1 (MO22089): Final efficacy outcomes for patients with advanced non-squamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (bev) or bev+pemetrexed (pem) after first-line (1L) bev-cisplatin (cis)-pem treatment (Tx). European Multidisciplinary Cancer Congress. Euro J Cancer 2011; 47:S16.
23. Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, et al. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/ bevacizumab followed by maintenance peme-trexed/bevacizumab versus paclitaxel/carboplatin/ bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009; 10:252-6.
24. Eastern Cooperative Oncology Group and National Cancer Institute. Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy In Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. From: http://clinicaltrials.gov/show/NCT01107626 Accessed: Jun 2012.
25. Lima ABC, Macedo LT, Sasse AD. Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A systematic review and meta-analysis. From: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022681. Accessed: May 2012.
26. Grothev A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26:5326-34.
27. Lynch TJ, Brahmer J, Fischbach N, Garst J, Kumar P, Spigel DR, et al. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS). J Clin Oncol 2008; 26:8077.
28. Nadler EE, Yu EE, Ravelo AA, Sing AA, Forsythe MM, Gruschkus SS. Bevacizumab treatment to progression after chemotherapy: Outcomes from a US community practice network. Oncologist 2011; 16:486-96.
29. F. Hoffmann La Roche Ltd. An open label, randomized, phase IIIb trial evaluating the efficacy and safety of standard of care + continuous bevacizumab treatment beyond progression of disease in patients with advanced NSCLC after first line treatment with bevacizumab plus a platinum doublets containing chemotherapy-AVAall (MO22097); From: http://clinicaltrials.gov/show/NCT01351415 Accessed: May 2012.
30. Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, Schrag D. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA 2012; 307:1593-601.
31. Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11:619-26.
32. de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol 2011; 29:1067-74.
33. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:1059-66.
34. Lee J, Hirsh V, Park K, Qin S, Blajman CR, Perng R, et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomised, double-blind phase III trial (ZEPHYR). J Clin Oncol 2010; S28:7525.
35. Scagliotti G, Govindan R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist 2010; 15:436-46.
36. Gatzemeier U, Eisen T, Santoro A, Paz-Ares L, Bennouna J, Liao M, et al. Sorafenib (S) + gemcitabine/cisplatin (GC) vs GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC): phase III NSCLC research experience utilizing sorafenib (NEXUS) trial. Transl Lung Cancer Res 2012; 1:72-7.
37. Bayer Health Care Pharmaceuticals. A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer NSCLC. (MISSION). From: www.clinicaltrials.gov/show/NCT00863746 Accessed: Jun 2012.
38. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Jr, Tsao A, et al. The BATTLE trial: Personalizingtherapy for lung cancer. Cancer Discov 2011; 1:44-53.
39. Herbst RS, Blumenschein GR, Jr, Kim ES, Lee J, Tsao AS, Alden CM, et al. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. J Clin Oncol 2010; 28:7609.
40. Gori B, Ricciardi S, Fulvi A, Intagliata S, Del Signore E, de Filippo M, et al. New antiangiogenics in non-small cell lung cancer treatment: Vargatef (BIBF 1120) and beyond. Ther Clin Risk Manag 2011; 7:429-40.
41. Boehringer Ingelheim Pharmaceuticals. LUME-Lung 1. BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non-Small Cell Lung Cancer. From: http://clinicaltrials.gov/show/NCT00805194. Accessed: May 2012.
42. Boehringer Ingelheim Pharmaceuticals. LUME Lung 2. BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC. From: http://clinicaltrials.gov/show/NCT00806819. Accessed: May 2012.
43. Haley J, Whittle N, Bennet P, Kinchington D, Ullrich A, Waterfield M, et al. The human EGF receptor gene: Structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res 1987; 1:375-96.
44. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Onco Hematol 1995; 19:183-232.
45. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 2002; 94:1593-611.
46. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth factor receptors: A review of clinical research with a focus on non-small cell lung cancer. Lancet Oncol 2003; 4:397-406.
47. Pederson MW, Meltorn M, Damstrup L, Poulsen HS. The type III EGFR mutation. Biological significance and potential target for anticancer therapy. Ann Oncol 2001; 12:745-60.
48. Janmaat ML, Giaccone G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc) 2003; 39:61-80.
49. Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest 1991; 9:553-62.
50. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer inAsia (IPASS). J Clin Oncol 2011; 29:2866.
51. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. OPTIMAL trial. N Eng J Med 2009; 361:947-57.
52. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12:735.
53. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, Von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-37.
54. D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011; 29:2066-70.
55. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118:257-62.
56. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239.
57. Leary AF, Castro DG, Nicholson AG, Ashley S, Wotherspoon A, O'Brien ME, et al. Establishing an EGFR mutation screening service for non-small cell lung cancer-Sample quality criteria and candidate histological predictors. Eur J Can 2012; 48:61-7.
58. Somaiah N, Garrett-Mayer E, Huang X, Wahlquist AE, Danenberg K, Simon GR, et al. Use of negative thyroid transcription factor (TTF-1) status to predict for negative epidermal growth factor receptor (EGFR) mutations (Mts) status with a high negative predictive value (NPV) in patients (pts) with adenocarcinomas (AC) of the lung. J Clin Oncol 2011; 29:7530.
59. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; S24-31.
60. Coudert B, Ciuleanu T, Park K, Wu YL, Giaccone G, Cappuzzo F. Survival benefit with erlotinib maintenance therapy relative to prior chemotherapeutic response: A subanalysis of the phase III SATURN study in NSCLC. From: https://www.webges.com/cslide/e6388cc/public/play_video/500. Accessed: May 2012.
61. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. NCIC BR.21 trial. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353:123-32.
62. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. A multi-institutional randomised phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21:2237-46.
63. Kris MG, Natale RB, Herbst RS, TJ Lynch Jr, D Prager, C P Belani, et al. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer patients who had failed platinum-and docetaxel-based regimens (IDEAL-2). Proc Am Soc Clin Oncol 2002; 21:292a.
64. Douillard JY, Kim E, Hirsh V, Mok T, Socinski M, Gervais R, et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: A randomised, open-label phase III study (INTEREST): PRS-02. J Thorac Oncol 2007; 2:S305-6.
65. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545-52.
66. Herbst RS, Prager D, Hermann R, Fehrenbaher L, Johnson BE, Sandler A, et al. TRIBUTE: A phase III trial of erlotinib HCl combined with carboplatin and paclitaxel chemotherapy in advanced NSCLC. J Clin Oncol 2005; 23:5892-9.
67. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22:777-84.
68. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004; 22:785-94.
69. Janne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012; 30:2063-9.
70. Lee JS, Park K, Kim SW, Lee DH, Kim HT, Han JY, et al. A randomised phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thor Oncol 2009; 4:AbstrPRS4.
71. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med 2010; 362:2380-8.
72. Mitsudomi T, Morita S, Yatabe Y, Shunichi N, Isamu O, Takashi S, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol 2012; 30:7521.
73. Massuti B, Morán T, Porta R, Queralt C, Cardenal F, Mayo C, et al. Multicenter prospective trial of customized erlotinib for advanced NSCLC patients with epidermal growth factor receptor mutations: Final results of Spanish Lung Cancer Group (SLCG) trial. J Clin Oncol 2009; 7;8023.
74. Jänne PA, Wang XF, Socinski MA, Crawford J, Capelletti M, Edelman MJ, et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/ paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 2010; 28:7503.
75. Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol. 2012; 30:3002-11.
76. Garassino MC, Martelli O, Bettini A, Floriani A, Copreni E, Calogero L, et al. TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol 2012: 30:7501.
77. Pirker R, Pereiera JR, Szezesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemo in patients with advanced NSCLC (FLEX): An open label phase III trial. Lancet 2009; 373:1525-31.
78. Carillio GG, Montanino A, Costanzo R, Sandomenico C, Piccirillo MC, Di Maio M, et al. Cetuximab in non-small-cell lung cancer. Expert Rev Anticancer Therapy 2012; 12:163-75.
79. Lynch TJ, Patel T, Dreisbach L, Heim WJ, Hermann RC, Paschold E, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28:911-7.
80. Christensen JG, Burrows J, Salgia R. cMET as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225:1-26.
81. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, et al. Ethnic differences and functional analysis of MET mutations in the lung cancer. Clin Cancer Res 2009; 15:5714-23.
82. Zucali PA, Ruiz MG, Giovannetti E, Destro A, Varella-Garcia M, Floor K, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. AnnOncol 2008; 19:1605-12.
83. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43.
84. Spigel DR, Ervin T, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy result from a randomized phase II study (OAM4558G) evaluating MetMab or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol. 2011; 29:7505.
85. Schiller JH, Akerley WL, Brugger W, Ferrari D, Garmey EG, Gerber DE, et al. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 28:7502.
86. Genentech with Hoffmann-La Roche. A Study of Onartuzumab (MetMAb) in Combination with Tarceva (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Cell Lung Cancer who have Received Chemotherapy for Advanced or Metastatic Disease (MetLung) trial. From: http://clinicaltrials.gov/show/NCT01456325. Accessed: Sep 2012.
87. Jänne PA, Shaw AT, Pereira JR, Gaelle J, Johan V, et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30:7503.
88. Mano H. Nonsolid oncogenes in solid tumors; EML4-ALK fusion genes in lung cancer. Cancer Sci 2008; 99:2349-55.
89. Manabu S, Shuji T, Kengo T, Young LC, Munehiro E, Toshihide U, et al. EML4 ALK mutations in lung cancer that confers resistance to ALK inhibitors. N Engl J Med 2010; 313:18:1734-9.
90. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcomes of patients with NSCLC who harbor EML4 ALK. J Clin Oncol 2009; 27:424.
91. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med 2010; 363:1693-703.
92. Riely G. Phase 2 data for crizotinib (PF-02341066) in ALK-positive advanced non-small cell lung cancer (NSCLC): PROFILE 1005. International Association for the Study on Lung Cancer, 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 Jul 2011. Abstr 031.05.
93. Pfizer Oncology. PROFILE 1007: A phase III trial of crizotinib (PF-02341066) versus standard of care in patients with NSCLC with a specific alterationof the anaplastic lymphoma kinase (ALK) gene. NPU00315. From: http://www.pfizer.com/files/news/ash/crizotinib_study_1007_backgrounder_2010.pdf. Accessed: Jun 2012.
94. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2005; 2:e313.
95. Pao W, Miller V, Politi KA, Riely GJ, Samwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinoma to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73.
96. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352:786-92.
97. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Barras AM, Gale CM, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR amplified lung cancer. J Clin Invest 2006; 116:2695-706.
98. Boehringer Ingelheim Pharmaceuticals. BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-Lung 1) From: http://clinicaltrials.gov/show/NCT00656136. Accessed: Jun 2012.
99. Yang JC, Schuler MH, Yamamoto N, O'Byrne KJ, Hirsh V, Mok T, et al. A multicentre, randomised, open-label phase III trial of BIBW 2992 versus chemotherapy (cisplatin /pemetrexed) as firstline treatment for patients with advanced and metastatic nonsmall cell lung cancer (NSCLC) harboring an EGFR mutation. J Clin Oncol 2012; 30:7500.
100. Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, et al. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines. Mol Cancer Res 2010; 8:1142-51.
101. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10:281-9.
102. Gua RH, Chen XF, Wang TS, Zhang ZY, Sun J, Shu YQ, et al. Subsequent chemotherapy reveals acquired TKI resistance and restores response to TKI in advanced NSCLC. BMC Cancer 2011; 11:9.